Probiotec Ltd
ASX:PBP
Probiotec Ltd
Revenue
Probiotec Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Probiotec Ltd
ASX:PBP
|
Revenue
AU$221.2m
|
CAGR 3-Years
28%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Revenue
AU$190.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Revenue
AU$237.6m
|
CAGR 3-Years
550%
|
CAGR 5-Years
77%
|
CAGR 10-Years
47%
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Revenue
AU$588.4k
|
CAGR 3-Years
56%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Revenue
AU$11.7m
|
CAGR 3-Years
59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Vita Life Sciences Ltd
ASX:VLS
|
Revenue
AU$74.2m
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
See Also
What is Probiotec Ltd's Revenue?
Revenue
221.2m
AUD
Based on the financial report for Dec 31, 2023, Probiotec Ltd's Revenue amounts to 221.2m AUD.
What is Probiotec Ltd's Revenue growth rate?
Revenue CAGR 10Y
13%
Over the last year, the Revenue growth was 8%. The average annual Revenue growth rates for Probiotec Ltd have been 28% over the past three years , 24% over the past five years , and 13% over the past ten years .